Evaluating the effect of astaxanthin supplement in patients with type 2 diabetes Treated by metformin

Evaluation of the effects of astaxanthin on markers related to autophagy and study of inflammatory activity by expression of microRNAs in type ? diabetic patients are treated with metformin

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190305042939N1

Enrollment

Registered

2019-06-17

Start date

2019-05-21

Completion date

Unknown

Last updated

2022-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes. Type 2 diabetes mellitus

Interventions

Intervention 1: Control group: Metformin /Placebo treated diabetic group. Intervention 2: Intervention group: Intervention group: Diabetic group treated with metformin / astaxanthin.This intervention

Eligibility

Sex/Gender

All

Age

20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes Treated by metformin Age: 20-60 years

Exclusion criteria

Exclusion criteria: Patients with type 1 diabetes Pregnant women Women in lactation Taking any antidiabetic drug other than metformin Patients with other endocrine disorders Take any other antioxidant supplement

Design outcomes

Primary

Measure	Time frame
Glycemic Indexes: Following the intervention, we expect the glycemic indexes of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: (Glycemic indexes in this study include fasting blood sugar, glycated hemoglobin, and insulin). Fasting blood Glucose: Colorimetric Method - Glycated Hemoglobin: High Performance Liquid Chromatography - Insulin: ELISA Technique.;Oxidative stress: Following the intervention, we expect the oxidative stress markers of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: The oxidative stress in this study is measured by markers that are: total antioxidant capacity, malondialdehyde, catalase and superoxide dismutase, all of which are measured by Spectrophotometry and with relevant reagents.;Tubular and glomerular Indexes: Following the intervention, we expect the tubular and glomerular Indexes of the patient group (treated with astaxantin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: Tubular and glomerular markers in this study are: cystatin C, microalbumin, creatinine and lipocalin-associated neutrophil gelatinase: ELISA technique.;Oxidative stress: Following the intervention, we expect the oxidative stress markers of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: The oxidative stress in this study is measured by markers that are:Total protein, malondialdehyde, 8-hyd	—

Measure

Time frame

Glycemic Indexes: Following the intervention, we expect the glycemic indexes of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: (Glycemic indexes in this study include fasting blood sugar, glycated hemoglobin, and insulin). Fasting blood Glucose: Colorimetric Method - Glycated Hemoglobin: High Performance Liquid Chromatography - Insulin: ELISA Technique.;Oxidative stress: Following the intervention, we expect the oxidative stress markers of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: The oxidative stress in this study is measured by markers that are: total antioxidant capacity, malondialdehyde, catalase and superoxide dismutase, all of which are measured by Spectrophotometry and with relevant reagents.;Tubular and glomerular Indexes: Following the intervention, we expect the tubular and glomerular Indexes of the patient group (treated with astaxantin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: Tubular and glomerular markers in this study are: cystatin C, microalbumin, creatinine and lipocalin-associated neutrophil gelatinase: ELISA technique.;Oxidative stress: Following the intervention, we expect the oxidative stress markers of the patients (treated with astaxanthin and metformin) to differ from the control group (placebo and metformin). Timepoint: Initially (before the intervention) and at the end (8 weeks after the intervention). Method of measurement: The oxidative stress in this study is measured by markers that are:Total protein, malondialdehyde, 8-hyd

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Movahedian Attar

Esfahan University of Medical Sciences

Movahedian.ahmad@gmail.com+98 31 3792 7048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026